Monoclonal anti-IgE antibody: A novel therapy for allergic airways disease

Annals of Allergy, Asthma and Immunology

Volumn 88, Issue 2, 2002, Pages 152-161

  Berger, William E ^a  

^a Southern California Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN E ANTIBODY; MONOCLONAL ANTIBODY; OMALIZUMAB; PLACEBO;

ADOLESCENT; ADULT; ALLERGIC REACTION; ALLERGIC RHINITIS; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EPITHELIUM CELL; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECEPTOR AFFINITY; RESPIRATORY EPITHELIUM; RESPIRATORY TRACT DISEASE; REVIEW; RISK BENEFIT ANALYSIS;

EID: 0036175217     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1081-1206(10)61989-8     Document Type: Review

References (75)

1. Current estimates from the National Health interview survey, 1996
2. The health economics of asthma and rhinitis. I. Assessing the economic impact
3. A cost of illness study of allergic rhinitis in the United States
4. Learning impairment and allergic rhinitis
5. Impact of upper respiratory allergic diseases on quality of life
6. How much asthma is really attributable to atopy?
7. Epidemiological study of the genetics and environment of asthma, bronchial hyperresponsiveness, and atopy: Phenotype issues
8. NAC Manchester Asthma and Allergy Study (NACMAAS): Risk factors for asthma and allergic disorders in adults
9. Benefits of high altitude allergen avoidance in atopic adolescents with moderate to severe asthma, over and above treatment with high dose inhaled steroids
10. Asthma
11. Human neutrophils express the high-affinity receptor for immunoglobulin E (FcεRI): Role in asthma
12. High-affinity IgE receptor on eosinophils is involved in defence against parasites
13. Dendritic cells in normal and asthmatic airways: Expression of the a subunit of the high affinity immunoglobulin E receptor (FcεRI-α)
14. Expression of the high-affinity receptor for IgE on bronchial epithelial cells of asthmatics
15. Elevation of total serum immunoglobulin E is associated with asthma in nonallergic individuals
16. High-affinity IgE receptor (FcεRI)-bearing cells in bronchial biopsies from atopic and nonatopic subjects
17. Association of asthma with serum IgE levels and skin-test reactivity to allergens
18. The role of CD23 in allergic disease
19. Therapeutic potential of anti-IgE antibodies
20. Treatment of allergic airways disease with anti-IgE
21. The binding site on human immunoglobulin E for its high affinity receptor
22. Humanization of an antibody directed against IgE
23. The B-cell binding site on human immunoglobulin E
24. Inhibition of allergic reactions with antibodies to IgE
25. Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE
26. Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys
27. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis
28. Down-regulation of Fc(ε)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody
29. Down-regulation of human basophil IgE and FcεRI-α surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo
30. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
31. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics
32. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab)
33. rhuMAb-E25 (omalizumab, Xolair) treatment allows sustained reduction of the need for inhaled corticosteroids in moderate/severe allergic asthma
34. Long-term improvement in asthma control and exacerbation frequency is achieved with omalizumab (Xolair) in patients with moderate-to-severe asthma
35. Omalizumab (Xolair) decreases the risk of serious asthma exacerbations requiring hospitalization in patients with moderate-to-severe allergic asthma
36. rhuMAb-25 (E25) improves asthma-specific quality of life in patients with allergic asthma
37. rhuMAb-E25 improves asthma-specific quality of life in patients with allergic asthma
38. rhuMAb-E25 (E25) improves quality of life (QoL) in children with allergic asthma
39. Evaluation of impairment of health related quality of life in asthma: Development of a questionnaire for use in clinical trials
40. Measuring quality of life in asthma
41. Measuring quality of life in children with asthma
42. Determining a minimal important change in a disease-specific quality of life questionnaire
43. Omalizumab (Xolair, rhuMAb-E25), a novel therapy for severe allergic asthma
44. Omalizumab (rhuMAb-E25) improves asthma-specific quality of life in patients with severe allergic asthma
45. rhuMAb-E25 in the treatment of seasonal allergic rhinitis (SAR)
46. Relationship between the clinical efficacy of rhuMAb-E25 (E25) and serum free IgE in seasonal allergic rhinitis
47. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis
48. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis
49. Xolair in the treatment of perennial allergic rhinitis
50. Omalizumab (Xolair) improves perennial allergic rhinitis in patients who were previously unresponsive to treatment with nasal steroids or immunotherapy
51. Inhibitory effects of an anti-IgE antibody E25 on allergen -induced early asthmatic response
52. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects
53. Treatment of allergic asthma with monoclonal anti-IgE antibody
54. Anti-inflammatory effects of a recombinant monoclonal anti-IgE (E25) in asthma
55. A pilot study of the effects of an anti-IgE antibody (E25) on airway inflammation in moderate-severe asthma
56. Exhaled nitric oxide, sensitization, and exposure to allergens in patients with asthma who are not taking inhaled steroids
57. Exhaled nitric oxide in children on a recombinant humanized monoclonal antibody, rhuMAb-E25 (omalizumab) during withdrawal of corticosteroids
58. Long-term safety and tolerability of Xolair-a double-blind, placebo-controlled study
59. Safety of anti-IgE monoclonal antibody rhuMAb-E25 (E25) in treatment of children with allergic asthma
60. Evidence of the long-term safety and tolerability of omalizumab from a large phase III study
61. Safety of readministration of rhuMAb-E25 in seasonal allergic rhinitis (SAR)
62. Omalizumab (Xolair, rhuMAb-E25) plus specific immunotherapy in children with seasonal allergic rhinitis is superior to specific immunotherapy alone
63. Combined effect of omalizumab (rhuMAb-E25, Xolair) and specific immunotherapy on in vitro leukotriene release
64. Disease management of atopic dermatitis: A practice parameter
65. Food allergy. Part 1: Immunopathogenesis and clinical disorders
66. Prevalence of peanut and tree nut allergy in the US determined by a random digit dial telephone survey
67. Fatalities due to anaphylactic reactions to foods
68. Food allergy. Part 2: Diagnosis and management
69. "Hidden" allergens in foods
70. Latex allergy
71. The prevalence of anti-latex IgE antibodies among registered nurses
72. Prevalence of IgE to natural rubber latex in unselected blood donors and performance characteristics of AlaSTAT testing
73. The prevalence of antilatex IgE antibodies in 1000 volunteer blood donors
74. Latex sensitization in health care workers and in the US general population
75. Specific immunotherapy with a standardized latex extract versus placebo in allergic healthcare workers